Title : CYP2C19 Loss-of-function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes.

Pub. Date : 2022 Feb

PMID : 34656068






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sulfonylureas (SUs) are predominantly metabolized by cytochrome p450 2C9 (CYP2C9) and cytochrome p450 2C19 (CYP2C19) enzymes. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens
2 Sulfonylureas (SUs) are predominantly metabolized by cytochrome p450 2C9 (CYP2C9) and cytochrome p450 2C19 (CYP2C19) enzymes. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens
3 Sulfonylureas (SUs) are predominantly metabolized by cytochrome p450 2C9 (CYP2C9) and cytochrome p450 2C19 (CYP2C19) enzymes. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens
4 Sulfonylureas (SUs) are predominantly metabolized by cytochrome p450 2C9 (CYP2C9) and cytochrome p450 2C19 (CYP2C19) enzymes. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens
5 CYP2C9 polymorphisms are associated with greater treatment response and hypoglycemic risk in SU users. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens